460-39-9

Usage

Uses

Used in Pharmaceutical Industry:
3,3,3-Trifluoropropylamine is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique properties, including the presence of fluorine atoms, contribute to the development of new drugs with improved pharmacokinetic and pharmacodynamic profiles.
Used in Agrochemical Industry:
In the agrochemical sector, 3,3,3-Trifluoropropylamine is utilized as a precursor in the production of agrochemicals. Its reactivity and ability to form stable compounds make it suitable for the creation of effective pesticides and other agricultural chemicals.
Used in Surfactant Production:
3,3,3-Trifluoropropylamine is employed as a key component in the manufacturing of surfactants. These surfactants are used in a variety of applications, such as detergents, emulsifiers, and dispersants, due to their ability to reduce surface tension and stabilize mixtures.
Used as a Reagent in Organic Synthesis:
3,3,3-Trifluoropropylamine functions as a reagent in various organic synthesis processes. Its reactivity allows for the formation of new chemical bonds and the creation of diverse organic compounds for research and industrial applications.
Used as a Solvent in Chemical Reactions:
Due to its ability to dissolve a wide range of substances, 3,3,3-Trifluoropropylamine is used as a solvent in chemical reactions. This facilitates the progress of reactions and can improve the yield and selectivity of the desired products.

InChI:InChI=1/C3H6F3N/c4-3(5,6)1-2-7/h1-2,7H2

Upstream product

• 460-35-5 3-chloro-1,1,1-trifluoropropane 
• 406-91-7 4,4,4-trifluorobutanoyl chloride 
• 347190-33-4 2-(3,3,3-trifluoropropyl)isoindoline-1,3-dione 
• 75-38-7 Vinylidene fluoride 
• 100-97-0 hexamethylenetetramine 
• 107-95-9 3-amino propanoic acid 
• 460-75-3 3,3,3-trifluoropropionamide 
• 460-37-7 1,1,1-trifluoro-3-iodopropane 
• 96650-83-8 1,2,3,4,9,9a-hexahydro-4AH-fluoren-4a-amine 

Downstream Products

• 114467-01-5 C₉H₉F₃NO₃S*H⁽¹⁺⁾ 
• 74788-86-6 1-(3,3,3-trifluoropropyl)-3-cyclohexylurea 
• 910484-10-5 6-chloro-4-hydroxy-4-phenyl-3-(2,2,2-trifluoroethyl)-3,4-dihydroquinazolin-2(1H)-one 
• 910484-11-6 6-fluoro-4-hydroxy-4-phenyl-3-(2,2,2-trifluoroethyl)-3,4-dihydroquinazolin-2(1H)-one 
• 910484-23-0 N-[4-chloro-2-(cyclopropylcarbonyl)phenyl]-N'-(2,2,2-trifluoroethyl)urea 
• 910484-13-8 6-chloro-4-(4-fluorophenyl)-4-hydroxy-3-(2,2,2-trifluoroethyl)-3,4-dihydroquinazolin-2(1H)-one 
• 910484-15-0 N-[3,4-difluoro-2-(4-fluorobenzoyl)phenyl]-N'-(2,2,2-trifluoroethyl)urea 
• 910484-16-1 5,6-difluoro-4-(4-fluorophenyl)-4-hydroxy-3-(2,2,2-trifluoroethyl)-3,4-dihydroquinazolin-2(1H)-one 
• 910484-21-8 6-chloro-4-(4-bromophenyl)-4-hydroxy-3-(2,2,2-trifluoroethyl)-3,4-dihydroquinazolin-2(1H)-one 
• 1032464-67-7 C₁₀H₉F₄NO₄S 
• 1239234-56-0 2-({(2-(4-chlorophenyl)-1,3-thiazol-4-yl)methyl}sulfanyl)-4-(4-(2-hydroxyethoxy)phenyl)-6-((3,3,3-trifluoropropyl)amino)pyridine-3,5-dicarbonitrile 
• 1314664-09-9 C₁₂H₁₃ClF₃NO 
• 1309682-24-3 4-(2-amino[1,2,4]triazolo[1,5-a]pyridin-6-yl)-N-(3,3,3-trifluoropropyl)benzamide 
• 112738-39-3 C₁₀H₉ClF₃NO 

Relevant academic research and scientific papers

Inhibitors of phenylethanolamine N-methyltransferase that are predicted to penetrate the blood-brain barrier: Design, synthesis, and evaluation of 3-fluoromethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinolines that possess low affinity toward the α2-adrenoceptor

(±)-7-Aminosulfonyl-3-fluoromethyl-1,2,3,4-tetrahydroisoquinoline (7) is one of the most potent and selective inhibitors of phenylethanolamine N-methyltransferase (PNMT) reported to date, but a blood-brain barrier (BBB) model indicates that it cannot penetrate the BBB. To increase the lipophilicity of 7 by addition of a nonpolar substituent to the sulfonamide nitrogen, a small library of (±)-3-fluoromethyl-7-(N-substituted aminosulfonyl)-1,2,3,4- tetrahydroisoquinolines was synthesized and evaluated as inhibitors of PNMT and for affinity at the α2-adrenoceptor. In addition, this library probed the PNMT active site surrounding the sulfonamide nitrogen of 7. Bulky substituents on the sulfonamide nitrogen are disfavored at the PNMT active site more so than at the α2-adrenoceptor (thus reducing selectivity). On the other hand, alkyl chains on the sulfonamide nitrogen that contain an electron dense atom, such as a fluorine, are favored in the PNMT active site and possess little α2-adrenoceptor affinity, thereby conferring good selectivity (>500). Several members of the library (8, 14, 17, and 18) have excellent PNMT inhibitory potency and selectivity and are predicted, on the basis of their ClogP value (>0.5), to penetrate the BBB to a significant extent. Compounds 17 and 18 are the most potent and selective PNMT inhibitors reported to date.

Isotopically-labeled polycyclic amine derivatives

STR1 A series of isotopically-labeled fluorenamine, dibenzofuranamine, and dibenzothiophenamine derivatives useful for diagnosing neurodegenerative disorders in mammals wherein a detectable amount of an isotape-labeled fluorenamine, dibenzofuranamine, or dibenzothiophenamine derivative is used.

Structural Effects on the Transition States of Imine-Forming Eliminations in N-Substituted O-(Arylsulfonyl)hydroxylamines

A series of amines with various alkyl and aryl substituents at C-1 were converted to the corresponding N-(arylsulfonoxy)amines, which served as precursors for base-promoted, imine-forming elimination.By varying the bases used to promote the elimination and by varying the leaving groups attached to nitrogen, the Broensted parameters β and βlgCH3 were determined.These were used to locate the transition state on the More O'Ferrall-Jencks energy surface for elimination.Substituents were found to influence the structure of the activated complex markedly.Resonance effects were most important, while inductive effects had little influence .

Process for preparing pyrazolopyridine compounds

Compounds of the formula (I): STR1 wherein R4 is hydrogen, D is oxygen or NR6, R1, R3, R6, R7 and R8 have defined values, and n is 1 or 2 are produced by internally cyclizing a compound of the formula (XV): STR2 wherein R19 is a value of R1 or hydrogen and, if R19 is hydrogen, reacting the cyclization product with R1 --Br and a weak base such as potassium carbonate.

CNS-Depressant pyrazolopyridines

Compounds of the formula (I): STR1 wherein R1, R3, R4, R7 and R8 are as described herein, D is oxygen or NR6, n is 1 or 2 and the physiologically acceptable salts thereof useful in reducing anxiety in an animal such as man. The compounds are potent anxiolytics having reduced side effects compared to known anxiolytics. Also pharmaceutical compositions, intermediates and methods of treatment and synthesis are described.